Metastatic head and neck squamous cell carcinoma (HNSCC) research hub

TACTI-003 (Two ACTive Immunotherapeutics): A multicenter, open label, randomized, Phase II trial to investigate a soluble LAG-3 fusion protein, eftilagimod alpha (efti; IMP321) in combination with pembrolizumab (PD-1 antagonist) for first line treatment of subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC)

This study looks at a new drug, efti, combined with an existing cancer drug, pembrolizumab, for head and neck cancer that has spread or returned. It aims to see if this combination shrinks tumours more effectively. Anyone over 18 can join.